RS60408B1 - Postupak za pripremanje (2z,5z)-5-(3-hloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međujedinjenja upotrebljena u pomenutom postupku - Google Patents
Postupak za pripremanje (2z,5z)-5-(3-hloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međujedinjenja upotrebljena u pomenutom postupkuInfo
- Publication number
- RS60408B1 RS60408B1 RS20200642A RSP20200642A RS60408B1 RS 60408 B1 RS60408 B1 RS 60408B1 RS 20200642 A RS20200642 A RS 20200642A RS P20200642 A RSP20200642 A RS P20200642A RS 60408 B1 RS60408 B1 RS 60408B1
- Authority
- RS
- Serbia
- Prior art keywords
- propylimino
- dihydroxypropoxy
- thiazolidin
- benzylidene
- tolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/77—Preparation of chelates of aldehydes or ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/81—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12180920 | 2012-08-17 | ||
PCT/IB2013/056662 WO2014027330A1 (en) | 2012-08-17 | 2013-08-15 | Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process |
EP13779378.2A EP2885266B1 (en) | 2012-08-17 | 2013-08-15 | Process for the preparation of (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process |
Publications (1)
Publication Number | Publication Date |
---|---|
RS60408B1 true RS60408B1 (sr) | 2020-07-31 |
Family
ID=46940231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20200642A RS60408B1 (sr) | 2012-08-17 | 2013-08-15 | Postupak za pripremanje (2z,5z)-5-(3-hloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međujedinjenja upotrebljena u pomenutom postupku |
Country Status (20)
Country | Link |
---|---|
US (1) | US9340518B2 (sr) |
EP (1) | EP2885266B1 (sr) |
JP (2) | JP6322630B2 (sr) |
KR (1) | KR101731739B1 (sr) |
CN (1) | CN104540800B (sr) |
CA (1) | CA2895172C (sr) |
CY (1) | CY1123300T1 (sr) |
DK (1) | DK2885266T3 (sr) |
ES (1) | ES2795105T3 (sr) |
HR (1) | HRP20200883T1 (sr) |
HU (1) | HUE050733T2 (sr) |
IL (1) | IL237198A (sr) |
LT (1) | LT2885266T (sr) |
MX (1) | MX350891B (sr) |
PL (1) | PL2885266T3 (sr) |
PT (1) | PT2885266T (sr) |
RS (1) | RS60408B1 (sr) |
SI (1) | SI2885266T1 (sr) |
TW (1) | TWI606036B (sr) |
WO (1) | WO2014027330A1 (sr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2617628T5 (es) | 2008-03-17 | 2020-06-01 | Actelion Pharmaceuticals Ltd | Régimen de dosificación para un agonista selectivo del receptor de S1P1 |
JP6322630B2 (ja) * | 2012-08-17 | 2018-05-09 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | (2Z,5Z)−5−(3−クロロ−4−((R)−2,3−ジヒドロキシプロポキシ)ベンジリデン)−2−(プロピルイミノ)−3−(o−トリル)チアゾリジン−4−オンの製造方法及び前記方法において使用される中間体 |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
MY188764A (en) | 2014-12-11 | 2021-12-30 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
CA3009713A1 (en) * | 2015-12-25 | 2017-06-29 | Crystal Pharmatech Co., Ltd. | Crystalline forms of ponesimod and preparation method thereof |
JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
US11220488B2 (en) | 2017-09-19 | 2022-01-11 | Teva Pharmaceuticals International Gmbh | Crystalline polymorph of Ponesimod |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
KR102365655B1 (ko) | 2018-11-29 | 2022-02-22 | 원광대학교 산학협력단 | 콩 발효 추출물을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 조성물 |
AU2020372647A1 (en) | 2019-10-31 | 2022-06-16 | Idorsia Pharmaceuticals Ltd | Combination of a CXCR7 antagonist with an S1P1 receptor modulator |
WO2023022896A1 (en) | 2021-08-17 | 2023-02-23 | Teva Czech Industries S.R.O | Polymorphs of ponesimod |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2023152691A1 (en) * | 2022-02-10 | 2023-08-17 | Metrochem Api Pvt Ltd | Process for the preparation of ponesimod and its intermediates thereof |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3077402A (en) | 1954-12-06 | 1963-02-12 | Polaroid Corp | Photographic color processes, products, and compositions |
NL270002A (sr) | 1960-10-08 | |||
GB1001479A (en) | 1962-10-10 | 1965-08-18 | Angeli Inst Spa | Glycerol ethers |
OA03835A (fr) | 1970-07-17 | 1971-12-24 | Rhone Poulenc Sa | Nouveaux dérivés de la thiazolidine, leur préparation et les compositions qui les contiennent. |
DE69123738T2 (de) | 1990-04-27 | 1997-07-03 | Orion Yhtymae Oy | Pharmakologisch aktive catecholderivate |
TW221689B (sr) | 1991-08-27 | 1994-03-11 | Otsuka Pharma Co Ltd | |
CN1037842C (zh) | 1993-02-26 | 1998-03-25 | 大制药株式会社 | 取代的噻唑烷衍生物及其药物组合物和用途 |
KR960022486A (ko) | 1994-12-29 | 1996-07-18 | 김준웅 | 신규 티아졸리딘-4-온 유도체 |
US6353006B1 (en) | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
ATE393150T1 (de) | 1999-09-14 | 2008-05-15 | Shionogi & Co | 2-imino-1,3-thiazin-derivate |
DK1142885T3 (da) | 1999-11-12 | 2007-02-26 | Fujimoto Brothers Co Ltd | 2-(N-cyanoimino)thiazolidin-4-on-derivater |
US20050019825A9 (en) | 2002-03-15 | 2005-01-27 | Qing Dong | Common ligand mimics: pseudothiohydantoins |
CA2493843C (en) | 2002-07-10 | 2012-04-17 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused-benzene derivatives |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
AU2003261434A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
NZ539873A (en) | 2002-11-22 | 2008-09-26 | Smithkline Beecham Corp | Novel chemical compounds, thiazolidin-4-one, thiazol-4-one |
US20040167192A1 (en) | 2003-01-16 | 2004-08-26 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
JP2007510136A (ja) | 2003-10-06 | 2007-04-19 | ソルヴィーアス アクチェンゲゼルシャフト | 分子状固体の結晶形態を並行検出する方法 |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
ES2352555T3 (es) | 2003-11-21 | 2011-02-21 | Actelion Pharmaceuticals Ltd. | Derivados de 5-(benc-(z)-iliden)tiazolidin-4-ona como agentes inmunosupresores. |
EP1718642A4 (en) | 2004-02-25 | 2010-11-24 | Glaxosmithkline Llc | NEW CHEMICAL COMPOUNDS |
WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
RU2478384C2 (ru) | 2004-11-29 | 2013-04-10 | Новартис Аг | Курс лечения с использованием агониста рецептора s1p |
WO2006094233A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N,n'-dicyclic isothiourea sirtuin modulators |
AU2006226020A1 (en) | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as sphingosine-l-phosphate-1 receptor agonists |
CN101180050B (zh) | 2005-03-23 | 2011-07-27 | 埃科特莱茵药品有限公司 | 作为鞘氨醇-1-磷酸盐-1受体激动剂的新颖噻吩衍生物 |
ES2365747T3 (es) | 2005-03-23 | 2011-10-10 | Actelion Pharmaceuticals Ltd. | Derivados de benzo[c]tiofeno hidrogenados como inmunomoduladores. |
JP2008546758A (ja) * | 2005-06-24 | 2008-12-25 | アクテリオン ファーマシューティカルズ リミテッド | 新規チオフェン誘導体 |
AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
ATE447568T1 (de) | 2006-01-24 | 2009-11-15 | Actelion Pharmaceuticals Ltd | Neue pyrinderivate |
US7879821B2 (en) | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
JP5253401B2 (ja) | 2006-09-07 | 2013-07-31 | アクテリオン ファーマシューティカルズ リミテッド | 免疫調節薬としてのピリジン−4−イル誘導体 |
NZ576059A (en) | 2006-09-08 | 2012-03-30 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
WO2008035239A1 (en) | 2006-09-21 | 2008-03-27 | Actelion Pharmaceuticals Ltd | Phenyl derivatives and their use as immunomodulators |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
EP2094676B1 (en) | 2006-11-23 | 2013-04-10 | Actelion Pharmaceuticals Ltd. | New process for the preparation of 2-iminothiazolidin-4-one derivatives |
NZ580454A (en) | 2007-03-16 | 2011-05-27 | Actelion Pharmaceuticals Ltd | Amino- pyridine derivatives as s1p1 /edg1 receptor agonists |
SI2195311T1 (sl) | 2007-08-17 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Derivati piridina kot modulatorji receptorja s1p1/edg1 |
ES2617628T5 (es) | 2008-03-17 | 2020-06-01 | Actelion Pharmaceuticals Ltd | Régimen de dosificación para un agonista selectivo del receptor de S1P1 |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
US20100160369A1 (en) | 2008-12-04 | 2010-06-24 | Exelixis, Inc. | S1P1 Agonists and Methods of Making And Using |
LT3409274T (lt) | 2008-12-22 | 2020-02-10 | Novartis Ag | Dozavimo schema s1p receptoriaus agonistui |
AR074825A1 (es) | 2008-12-22 | 2011-02-16 | Novartis Ag | Regimen de dosificacion de un agonista de los receptores de s1p, metodo de tratamiento y kit |
JP6322630B2 (ja) * | 2012-08-17 | 2018-05-09 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | (2Z,5Z)−5−(3−クロロ−4−((R)−2,3−ジヒドロキシプロポキシ)ベンジリデン)−2−(プロピルイミノ)−3−(o−トリル)チアゾリジン−4−オンの製造方法及び前記方法において使用される中間体 |
-
2013
- 2013-08-15 JP JP2015527061A patent/JP6322630B2/ja active Active
- 2013-08-15 PT PT137793782T patent/PT2885266T/pt unknown
- 2013-08-15 HU HUE13779378A patent/HUE050733T2/hu unknown
- 2013-08-15 MX MX2015002127A patent/MX350891B/es active IP Right Grant
- 2013-08-15 DK DK13779378.2T patent/DK2885266T3/da active
- 2013-08-15 EP EP13779378.2A patent/EP2885266B1/en active Active
- 2013-08-15 PL PL13779378T patent/PL2885266T3/pl unknown
- 2013-08-15 ES ES13779378T patent/ES2795105T3/es active Active
- 2013-08-15 WO PCT/IB2013/056662 patent/WO2014027330A1/en active Application Filing
- 2013-08-15 RS RS20200642A patent/RS60408B1/sr unknown
- 2013-08-15 KR KR1020157006474A patent/KR101731739B1/ko active IP Right Grant
- 2013-08-15 US US14/422,167 patent/US9340518B2/en active Active
- 2013-08-15 CN CN201380042658.2A patent/CN104540800B/zh active Active
- 2013-08-15 CA CA2895172A patent/CA2895172C/en active Active
- 2013-08-15 SI SI201331742T patent/SI2885266T1/sl unknown
- 2013-08-15 LT LTEP13779378.2T patent/LT2885266T/lt unknown
- 2013-08-16 TW TW102129570A patent/TWI606036B/zh active
-
2015
- 2015-02-12 IL IL237198A patent/IL237198A/en active IP Right Grant
-
2017
- 2017-04-13 JP JP2017079804A patent/JP6424250B2/ja active Active
-
2020
- 2020-06-02 HR HRP20200883TT patent/HRP20200883T1/hr unknown
- 2020-06-11 CY CY20201100532T patent/CY1123300T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT2885266T (pt) | 2020-05-29 |
MX2015002127A (es) | 2015-05-11 |
IL237198A0 (en) | 2015-04-30 |
CA2895172A1 (en) | 2014-02-20 |
ES2795105T3 (es) | 2020-11-20 |
TWI606036B (zh) | 2017-11-21 |
HRP20200883T1 (hr) | 2020-09-04 |
MX350891B (es) | 2017-09-22 |
TW201408634A (zh) | 2014-03-01 |
JP2015530373A (ja) | 2015-10-15 |
CA2895172C (en) | 2020-08-18 |
LT2885266T (lt) | 2020-07-10 |
WO2014027330A1 (en) | 2014-02-20 |
JP6424250B2 (ja) | 2018-11-14 |
JP2017160223A (ja) | 2017-09-14 |
JP6322630B2 (ja) | 2018-05-09 |
KR20150042277A (ko) | 2015-04-20 |
CY1123300T1 (el) | 2021-12-31 |
US9340518B2 (en) | 2016-05-17 |
PL2885266T3 (pl) | 2020-11-16 |
EP2885266B1 (en) | 2020-03-18 |
CN104540800A (zh) | 2015-04-22 |
EP2885266A1 (en) | 2015-06-24 |
SI2885266T1 (sl) | 2020-10-30 |
HUE050733T2 (hu) | 2021-01-28 |
US20150203459A1 (en) | 2015-07-23 |
KR101731739B1 (ko) | 2017-05-11 |
DK2885266T3 (da) | 2020-06-08 |
IL237198A (en) | 2017-12-31 |
CN104540800B (zh) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE050733T2 (hu) | Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék | |
IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
IL253700B (en) | Pharmaceutical preparations containing n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1, 2-diamine | |
IL245882B (en) | Process for the preparation of n-[(3-aminooxetane-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazepine-4-yl)-6-methyl-quinazoline- 4-Amin | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
IL239940B (en) | History of 2-[3-(diazolyl)phenyl]-3,1-thiazole-5-carboxylic acid and intermediates obtained in the process for their preparation | |
EP3403675A4 (en) | VIRION ADENO-ASSOCIATED VIRAL FOR ITS USE IN THE TREATMENT OF EPILEPSY | |
BR112013022523A2 (pt) | uso de glicopirrolato para o tratamento de taquicardia | |
HUE057257T2 (hu) | Folyékony készítmény gyomor- és nyelõcsõ reflux kezelésében történõ alkalmazásra | |
EP3372590A4 (en) | Compounds having agonistic effect for gpr84, preparation method for compounds and use of compounds | |
MA39912B1 (fr) | Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. | |
EP3175851A4 (en) | Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition | |
RS62941B1 (sr) | Proces za pripremanje n-((1r,2s,sr)-5-(terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oksopirolidin-1-il)cikloheksil)acetamida | |
BR112015001169A2 (pt) | polimorfo, uso do polimorfo, composição farmacêutica e uso para preparar o polimorfo | |
GB201513543D0 (en) | Compositions for use in the treatment of diabetes | |
EP3436009A4 (en) | NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 USEFUL IN THE TREATMENT OF MATURE BRAIN LESIONS | |
HUP1400105A2 (hu) | Nanostrukturált ibuprofent, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra | |
TH122396B (th) | สารยึดติดแบบสารกระจายตัวชนิดใหม่, กรรมวิธีสำหรับเตรียมสารเหล่านั้น และการใช้ของสารนั้น |